Analysts predict that Endocyte (NASDAQ:ECYT) will announce earnings per share (EPS) of ($0.19) for the current quarter, Zacks reports. Zero analysts have made estimates for Endocyte’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.16). Endocyte reported earnings of ($0.27) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Endocyte will report full-year earnings of ($0.76) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.70). For the next year, analysts forecast that the company will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.90) to ($0.72). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Endocyte.
Get Endocyte alerts:
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The business had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the company earned ($0.26) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year.
ECYT has been the topic of several recent research reports. BidaskClub upgraded shares of Endocyte from a “buy” rating to a “strong-buy” rating in a research report on Friday. ValuEngine raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Cowen raised shares of Endocyte from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 27th. Finally, Wells Fargo began coverage on shares of Endocyte in a research note on Friday, March 9th. They issued an “outperform” rating for the company. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Endocyte has a consensus rating of “Buy” and an average target price of $9.00.
In other Endocyte news, VP Christopher P. Leamon sold 5,036 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $9.07, for a total value of $45,676.52. Following the completion of the transaction, the vice president now directly owns 143,470 shares of the company’s stock, valued at $1,301,272.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 14.86% of the company’s stock.
Several large investors have recently modified their holdings of ECYT. Bank of New York Mellon Corp grew its position in shares of Endocyte by 46.5% during the 4th quarter. Bank of New York Mellon Corp now owns 51,313 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 16,283 shares during the period. BlackRock Inc. grew its position in shares of Endocyte by 223.7% during the 4th quarter. BlackRock Inc. now owns 1,138,791 shares of the biopharmaceutical company’s stock worth $4,875,000 after buying an additional 786,933 shares during the period. EAM Investors LLC acquired a new stake in shares of Endocyte during the 4th quarter worth approximately $420,000. Geode Capital Management LLC grew its position in shares of Endocyte by 15.6% during the 4th quarter. Geode Capital Management LLC now owns 241,498 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 32,603 shares during the period. Finally, AXA acquired a new stake in shares of Endocyte during the 4th quarter worth approximately $101,000. Institutional investors own 29.10% of the company’s stock.
NASDAQ ECYT opened at $10.89 on Friday. The firm has a market capitalization of $745.56, a price-to-earnings ratio of -10.89 and a beta of 0.47. Endocyte has a 52-week low of $1.17 and a 52-week high of $11.54.
Endocyte Company Profile
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Get a free copy of the Zacks research report on Endocyte (ECYT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com